Evotec SE (ETR:EVT)

Revenue by Segment

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Discovery and Preclinical Development	529.28M	611.55M	672.98M	702.02M	-
Discovery and Preclinical Development Growth	-13.45%	-9.13%	-4.14%	-	-
Just - Evotec Biologics	259.59M	186.62M	108.45M	49.43M	-
Just - Evotec Biologics Growth	39.10%	72.08%	119.41%	-	-
Intersegment Elimination	-496.00K	-1.21M	-	-	-139.12M
EVT Execute	-	-	-	-	610.17M
EVT Execute Growth	-	-	-	-	19.67%
EVT Innovate	-	-	-	-	146.98M
EVT Innovate Growth	-	-	-	-	37.58%
Total	788.37M	796.97M	781.43M	751.45M	618.03M
Total Growth	-1.08%	1.99%	3.99%	21.59%	23.38%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
USA	431.51M	445.86M	459.42M	407.75M	-
USA Growth	-3.22%	-2.95%	12.67%	-	-
Germany	25.29M	32.90M	34.13M	58.90M	-
Germany Growth	-23.13%	-3.60%	-42.04%	-	-
France	19.86M	19.91M	32.01M	32.27M	-
France Growth	-0.28%	-37.79%	-0.83%	-	-
United Kingdom	61.72M	92.52M	86.37M	115.26M	-
United Kingdom Growth	-33.28%	7.12%	-25.06%	-	-
Switzerland	161.61M	109.04M	64.92M	22.00K	-
Switzerland Growth	48.21%	67.95%	295009.09%	-	-
Rest of the World	77.09M	82.28M	95.15M	126.70M	-
Rest of the World Growth	-6.32%	-13.53%	-24.90%	-	-
Unallocated	11.29M	14.45M	9.42M	10.55M	-
Unallocated Growth	-21.84%	53.45%	-10.75%	-	-
Total	788.37M	796.97M	781.43M	751.45M	-
Total Growth	-1.08%	1.99%	3.99%	-	-

Source: S&P Global Market Intelligence.